Find Reports
Select Report Type
Reimbursement Review
Displaying 451 - 475 of 1422
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| Opdivo for Melanoma Adjuvant T... | Opdivo | Nivolumab | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | PC0147-000 | |||
| Adcetris for Hodgkin Lymphoma ... | Adcetris (Resubmission) | Brentuximab Vedotin | Hodgkin lymphoma (HL) | Do not reimburse | Complete | PC0145-000 | |||
| tofacitinib | Xeljanz | tofacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | SR0572-000 | |||
| Nusinersen | Spinraza | Nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | SR0576-000 | |||
| Cabometyx for Renal Cell Carci... | Cabometyx | Cabozantinib | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | PC0163-000 | |||
| ertugliflozin | Steglatro | ertugliflozin | Diabetes mellitus, Type 2 | Do not reimburse | Complete | SR0565-000 | |||
| ertugliflozin and metformin | Segluromet | ertugliflozin and metformin hydrochloride | Diabetes mellitus, Type 2 | Do not reimburse | Complete | SR0566-000 | |||
| Lenvima for Renal Cell Carcino... | Lenvima | Lenvatinib | Renal Cell Carcinoma (RCC) | Do not reimburse | Complete | PC0140 -000 | |||
| Tagrisso for Non-Small Cell Lu... | Tagrisso | Osimertinib | Non-Small Cell Lung Cancer (NSCLC) (first line) | Reimburse with clinical criteria and/or conditions | Complete | PC0137-000 | |||
| sucroferric oxyhydroxide | Velphoro | sucroferric oxyhydroxide | Hyperphosphatemia, end-stage renal disease | Reimburse with clinical criteria and/or conditions | Complete | SR0571-000 | |||
| lixisenatide + insulin glargin... | Soliqua | lixisenatide + insulin glargine | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | SR0564-000 | |||
| fluticasone propionate | Aermony RespiClick | fluticasone propionate | Asthma | Reimburse with clinical criteria and/or conditions | Complete | SR0539-000 | |||
| fluticasone propionate / salme... | Arbesda RespiClick | fluticasone propionate / salmeterol xinafoate | Asthma | Reimburse with clinical criteria and/or conditions | Complete | SR0540-000 | |||
| Opdivo for Hepatocellular Carc... | Opdivo | Nivolumab | Metastatic Hepatocellular Carcinoma (HCC) | Do not reimburse | Complete | PC0134-000 | |||
| Perjeta-Herceptin Combo Pack f... | Perjeta-Herceptin Combo Pack | Pertuzumab-Trastuzumab Combo Pack | Early Breast Cancer | Do not reimburse | Complete | PC0127-000 | |||
| Rivaroxaban | Xarelto | Rivaroxaban | Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. | Reimburse with clinical criteria and/or conditions | Complete | SR0569-000 | |||
| Opdivo in combo with Yervoy fo... | Opdivo in combination with Yervoy | Nivolumab in combination with Ipilimumab | Advanced or Metastatic Renal Cell Carcinoma (RCC). | Reimburse with clinical criteria and/or conditions | Complete | PC0132-000 | |||
| Gazyva for Follicular Lymphom... | Gazyva | Obinutuzumab | Follicular Lymphoma (previously untreated) | Do not reimburse | Complete | PC0126-000 | |||
| Erleada for Castrate Resistant... | Erleada | Apalutamide | non-metastatic castrate resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0133-000 | |||
| bictegravir/emtricitabine/teno... | Biktarvy | bictegravir/emtricitabine/tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | SR0567-000 | |||
| dexamethasone | Ozurdex | dexamethasone | Diabetic macular edema | Do not reimburse | Complete | SR0535-000 | |||
| ozenoxacin | Ozanex | ozenoxacin | Impetigo | Do not reimburse | Complete | SR0553-000 | |||
| cladribine | Mavenclad | cladribine | Multiple Sclerosis, relapsing-remitting | Reimburse with clinical criteria and/or conditions | Complete | SR0546-000 | |||
| Tapentadol Hydrochloride | Nucynta | tapentadol hydrochloride | pain, severe | Do not reimburse | Complete | SR0563-000 | |||
| sebelipase alfa | Kanuma | sebelipase alfa | Lysosomal acid lipase deficiency | Reimburse with clinical criteria and/or conditions | Complete | SR0544-000 |
Health Technology Review
Displaying 451 - 475 of 600
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 451 - 475 of 2132
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| HR positive, HER2 negative breast cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0041-000 | |||
| Renal Denervation | Health Technology Review | Rapid Review | Completed | RC1532-000 | |||
| Large B cell lymphoma | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0040-000 | |||
| efgartigimod alfa | Reimbursement Review | Complete | SR0782-000 | ||||
| Long-Term Use of Omalizumab for Chronic Idiopathic Urticaria | Health Technology Review | Technology Review | Completed | HC0053-000 | |||
| ibrutinib | Reimbursement Review | Complete | PC0328-000 | ||||
| calaspargase pegol | Reimbursement Review | Complete | PC0321-000 | ||||
| Patterns in Utilization of Long-Acting Inhaled Drugs for the Treatment of Chronic Obstructive Pulmonary Disease | Health Technology Review | Technology Review | In Progress | HC0086 -000 | |||
| Prostate Cancer | Reimbursement Review | Provisional Funding Algorithm | Completed | PH0039-000 | |||
| CADTH Pharmaceutical Reviews Update — Issue 45 | Reimbursement Review | Pharmaceutical Review Update | |||||
| semaglutide | Reimbursement Review | Complete | SR0594-000 | ||||
| semaglutide | Reimbursement Review | Complete | SR0637-000 | ||||
| Empagliflozin | Reimbursement Review | Complete | SR0427-000 | ||||
| Dapagliflozin | Reimbursement Review | Complete | SR0428-000 | ||||
| dulaglutide | Reimbursement Review | Complete | SR0462-000 | ||||
| dapagliflozin/metformin hydrochloride | Reimbursement Review | Complete | SR0468-000 | ||||
| Empagliflozin and metformin | Reimbursement Review | Complete | SR0489-000 | ||||
| Linagliptin-metformin | Reimbursement Review | Complete | SR0306-000 | ||||
| Saxagliptin | Reimbursement Review | Complete | SR0329-000 | ||||
| Saxagliptin + Metformin | Reimbursement Review | Complete | SR0348-000 | ||||
| Canagliflozin | Reimbursement Review | Complete | SR0370-000 | ||||
| Sitagliptin phosphate | Reimbursement Review | Complete | SR0181-000 | ||||
| Sitagliptin phosphate monohydrate / metformin hydrochloride | Reimbursement Review | Complete | SR0182-000 | ||||
| Linagliptin | Reimbursement Review | Complete | SR0244-000 | ||||
| Colorectal cancer | Reimbursement Review | Provisional Funding Algorithm | Withdrawn | PH0043-000 |